Asked by: Peter Bottomley (Conservative - Worthing West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, for how many months Mr Aditya Agrawal was (a) employed and (b) not suspended by East Lancashire Hospitals Trust.
Answered by Jeremy Hunt - Chancellor of the Exchequer
This is an employer and employee matter between the East Lancashire Hospitals NHS Trust and Mr Aditya Agrawal respectively. The Department cannot comment on individual employment matters that are the responsibility of independent organisations, and that are subject to ongoing legal proceedings or on matters relating to individual clinical cases or other personal information. We understand that the cost to East Lancashire Trust of legal proceedings concerning Mr Agrawal is £296,848.42 to date, and that the Trust does not have insurance costs for legal awards in the event of the Trust or one of its employees being subject to legal action for defamation.
Asked by: Peter Bottomley (Conservative - Worthing West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what assessment he has made of the potential (a) effectiveness and (b) value for money of providing pre-exposure prophylaxis for HIV.
Answered by Jane Ellison
Pre-exposure Prophylaxis (PrEP) is a new use of HIV drugs which has shown clinical effectiveness in research trials at preventing HIV in people at high risk of getting HIV such as men who have sex with men (MSM) and people with HIV-positive partners. The drug used in the trials, Truvada, is not yet licenced for use as PrEP. Public Health England (PHE) has undertaken modelling work looking at cost-effectiveness of PrEP. Much depends on the price of the drugs and HIV prevalence in the target group. However, as with any new intervention, PrEP now needs to be properly assessed in relation to cost effectiveness to see how it could be commissioned in the most sustainable and integrated way and how it compares with other cost-effective approaches. The Department is considering this with PHE, NHS England and the National Institute for Health and Care Excellence.
A wide range of stakeholders were included in the initial work by NHS England on PrEP including the Department of Health, PHE, the Medical Research Council, voluntary organisations and Genitourinary and HIV Clinicians. NHS England will be building on the work to date by making available up to £2 million over the next two years to run a number of early implementer sites. These will be undertaken in conjunction with PHE.
The data on new HIV diagnosis is available in table 1a in the following link:
As part of the PROUD study, PHE has assessed how many men may be considered high risk but it is not possible to estimate how many would seek to access PrEP.
Asked by: Peter Bottomley (Conservative - Worthing West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what steps he is taking to ensure that pre-exposure prophylaxis commissioning is targeted at people most at risk of HIV infection.
Answered by Jane Ellison
Pre-exposure Prophylaxis (PrEP) is a new use of HIV drugs which has shown clinical effectiveness in research trials at preventing HIV in people at high risk of getting HIV such as men who have sex with men (MSM) and people with HIV-positive partners. The drug used in the trials, Truvada, is not yet licenced for use as PrEP. Public Health England (PHE) has undertaken modelling work looking at cost-effectiveness of PrEP. Much depends on the price of the drugs and HIV prevalence in the target group. However, as with any new intervention, PrEP now needs to be properly assessed in relation to cost effectiveness to see how it could be commissioned in the most sustainable and integrated way and how it compares with other cost-effective approaches. The Department is considering this with PHE, NHS England and the National Institute for Health and Care Excellence.
A wide range of stakeholders were included in the initial work by NHS England on PrEP including the Department of Health, PHE, the Medical Research Council, voluntary organisations and Genitourinary and HIV Clinicians. NHS England will be building on the work to date by making available up to £2 million over the next two years to run a number of early implementer sites. These will be undertaken in conjunction with PHE.
The data on new HIV diagnosis is available in table 1a in the following link:
As part of the PROUD study, PHE has assessed how many men may be considered high risk but it is not possible to estimate how many would seek to access PrEP.
Asked by: Peter Bottomley (Conservative - Worthing West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, how many people were diagnosed with HIV in each of the last 10 years.
Answered by Jane Ellison
Pre-exposure Prophylaxis (PrEP) is a new use of HIV drugs which has shown clinical effectiveness in research trials at preventing HIV in people at high risk of getting HIV such as men who have sex with men (MSM) and people with HIV-positive partners. The drug used in the trials, Truvada, is not yet licenced for use as PrEP. Public Health England (PHE) has undertaken modelling work looking at cost-effectiveness of PrEP. Much depends on the price of the drugs and HIV prevalence in the target group. However, as with any new intervention, PrEP now needs to be properly assessed in relation to cost effectiveness to see how it could be commissioned in the most sustainable and integrated way and how it compares with other cost-effective approaches. The Department is considering this with PHE, NHS England and the National Institute for Health and Care Excellence.
A wide range of stakeholders were included in the initial work by NHS England on PrEP including the Department of Health, PHE, the Medical Research Council, voluntary organisations and Genitourinary and HIV Clinicians. NHS England will be building on the work to date by making available up to £2 million over the next two years to run a number of early implementer sites. These will be undertaken in conjunction with PHE.
The data on new HIV diagnosis is available in table 1a in the following link:
As part of the PROUD study, PHE has assessed how many men may be considered high risk but it is not possible to estimate how many would seek to access PrEP.
Asked by: Peter Bottomley (Conservative - Worthing West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, with whom NHS England's specialised commissioning service has consulted in the past 18 months in preparation for the planned public consultation on pre-exposure prophylaxis.
Answered by Jane Ellison
Pre-exposure Prophylaxis (PrEP) is a new use of HIV drugs which has shown clinical effectiveness in research trials at preventing HIV in people at high risk of getting HIV such as men who have sex with men (MSM) and people with HIV-positive partners. The drug used in the trials, Truvada, is not yet licenced for use as PrEP. Public Health England (PHE) has undertaken modelling work looking at cost-effectiveness of PrEP. Much depends on the price of the drugs and HIV prevalence in the target group. However, as with any new intervention, PrEP now needs to be properly assessed in relation to cost effectiveness to see how it could be commissioned in the most sustainable and integrated way and how it compares with other cost-effective approaches. The Department is considering this with PHE, NHS England and the National Institute for Health and Care Excellence.
A wide range of stakeholders were included in the initial work by NHS England on PrEP including the Department of Health, PHE, the Medical Research Council, voluntary organisations and Genitourinary and HIV Clinicians. NHS England will be building on the work to date by making available up to £2 million over the next two years to run a number of early implementer sites. These will be undertaken in conjunction with PHE.
The data on new HIV diagnosis is available in table 1a in the following link:
As part of the PROUD study, PHE has assessed how many men may be considered high risk but it is not possible to estimate how many would seek to access PrEP.
Asked by: Peter Bottomley (Conservative - Worthing West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, if he will estimate how many at-risk men in which areas will (a) not receive and (b) receive pre-exposure prophylaxis for HIV in each of the next five years.
Answered by Jane Ellison
Pre-exposure Prophylaxis (PrEP) is a new use of HIV drugs which has shown clinical effectiveness in research trials at preventing HIV in people at high risk of getting HIV such as men who have sex with men (MSM) and people with HIV-positive partners. The drug used in the trials, Truvada, is not yet licenced for use as PrEP. Public Health England (PHE) has undertaken modelling work looking at cost-effectiveness of PrEP. Much depends on the price of the drugs and HIV prevalence in the target group. However, as with any new intervention, PrEP now needs to be properly assessed in relation to cost effectiveness to see how it could be commissioned in the most sustainable and integrated way and how it compares with other cost-effective approaches. The Department is considering this with PHE, NHS England and the National Institute for Health and Care Excellence.
A wide range of stakeholders were included in the initial work by NHS England on PrEP including the Department of Health, PHE, the Medical Research Council, voluntary organisations and Genitourinary and HIV Clinicians. NHS England will be building on the work to date by making available up to £2 million over the next two years to run a number of early implementer sites. These will be undertaken in conjunction with PHE.
The data on new HIV diagnosis is available in table 1a in the following link:
As part of the PROUD study, PHE has assessed how many men may be considered high risk but it is not possible to estimate how many would seek to access PrEP.